1037P Activating strong anti-tumor immunity with PTPN2/PTPN1 inhibitor: AC484
Hakimeh Ebrahimi-Nik(Broad Institute), Robert T. Manguso(Broad Institute), Karen E. Yates(Broad Institute), Omar I. Avila(Broad Institute), Marcia N. Paddock(California State University, San Marcos), Arvin Iracheta‐Vellve(Broad Institute), Jennifer M. Frost(Mount Sinai Hospital), Philip R. Kym(AbbVie (United States)), Clay Beauregard, Elliot P. Farney(AbbVie (United States)), Kathleen A. McGuire(AbbVie (United States)), Keith M. Hamel(AbbVie (United States)), Kira E. Olander(Broad Institute), Christina K. Baumgartner(AbbVie (United States)), Thomas Davis(Broad Institute), Mark A. Matulenko(AbbVie (United States)), ChetanN Patel(Enzo Life Sciences (United States)), Geoff T. Halvorsen(AbbVie (United States))
Cited by 0
Related Papers
An expanded universe of cancer targets
|Cell|2021|221
Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice
|PLoS ONE|2017|114
Melanoma and microbiota: Current understanding and future directions
|Cancer Cell|2023|78